A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

Adrian Bot, Mark Ahn, Marnix Bosch, Dirk Brockstedt, Lisa H. Butterfield, Andrew Cornforth, Richard Harrop, W. M. Kast, Richard Koya, Francesco Marincola, Kim Margolin, Candice McCoy, Graham Pawelec, John Rothman, Teresa Ramirez-Montagut, Jeffrey Schlom, Pramod Srivastava, Sarah Wallis, Steffen Walter, Ena WangJohn Waslif

Research output: Contribution to journalArticle

1 Citation (Scopus)


While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.

Original languageEnglish
Article number218
JournalJournal of translational medicine
Issue number1
Publication statusPublished - 5 Nov 2012


ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bot, A., Ahn, M., Bosch, M., Brockstedt, D., Butterfield, L. H., Cornforth, A., Harrop, R., Kast, W. M., Koya, R., Marincola, F., Margolin, K., McCoy, C., Pawelec, G., Rothman, J., Ramirez-Montagut, T., Schlom, J., Srivastava, P., Wallis, S., Walter, S., ... Waslif, J. (2012). A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. Journal of translational medicine, 10(1), [218]. https://doi.org/10.1186/1479-5876-10-218